Pomalyst and Zovia 1/35e

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Pomalidomide can cause dangerous blood clots, and using it together with ethinyl estradiol may increase the risk. Also, the risk is increased with age, cigarette smoking, high blood pressure, or high cholesterol. Blood clots can lead to complications such as heart attack, pulmonary embolism (blockage of an artery in the lung), and stroke. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should seek immediate medical attention if you experience potential signs and symptoms of blood clots such as chest pain; shortness of breath; difficulty breathing; coughing up blood; sudden loss of vision; pain, redness or swelling in an arm or leg; and numbness or weakness on one side of the body. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR CLOSELY: Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of pomalidomide. Deep venous thrombosis (DVT) and pulmonary embolism (PE) occur in patients with multiple myeloma treated with pomalidomide. All patients in the premarketing clinical trial were required to receive prophylactic antithrombotic treatment (81% aspirin, 16% warfarin, 21% heparin, 3% clopidogrel). The rate of DVT or PE was 3%.

MANAGEMENT: Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving pomalidomide. Prophylactic antithrombotic measures should be considered after assessing underlying risk factors such as health history and concomitant medications. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.

Pomalyst

Generic Name: pomalidomide

Brand name: Pomalyst

Synonyms: n.a.

What is Pomalyst?

Zovia 1/35e

Generic Name: ethinyl estradiol / ethynodiol

Brand name: Kelnor, Zovia 1/35, Zovia 1/50, Demulen 1/35, Demulen 1/50, Zovia 1/35e, Kelnor 1/50, Kelnor 1/35, Zovia 1/50e

Synonyms: Zovia 1/35, Zovia 1/35E

What is Zovia 1/35e?